M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout BioPharma DiveThe deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai.M&A / DealsNeuroscienceRead full story pharminent March 31, 2026 (Last updated: April 1, 2026) BioPharma Dive The deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai. M&A / DealsNeuroscienceRead full story Post navigation Previous: Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis BuyNext: Novo hits back at rivals with cut-price Wegovy subscriptions Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
